Srs Capital Advisors, Inc. Summit Therapeutics Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 1,019 shares of SMMT stock, worth $22,316. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,019Holding current value
$22,316% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$509 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$193 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$90.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$64.9 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.41B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...